• Vir Biotechnology recently announced that it will present Phase 2 SOLSTICE trial data on its tobevibart and elebsiran combination for chronic hepatitis delta at the EASL Congress 2026 in Barcelona, highlighting an investigational monthly subcutaneous regimen that targets the virus at multiple points in its life cycle.
• This update underscores Vir’s attempt to address a highly aggressive, carcinogenic liver disease with no approved treatments in the US by pairing a broadly neutralizing monoclonal antibody with an siRNA therapy aimed at suppressing hepatitis B surface antigen.
• With Vir preparing to share Phase 2 SOLSTICE data on its hepatitis delta combination, we’ll assess how this shapes its investment narrative.

AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Vir Biotechnology Investment Narrative Recap

To own Vir Biotechnology, you need to believe its chronic hepatitis delta and PRO XTEN oncology platforms can eventually turn heavy R&D spending and persistent losses into a sustainable business. The upcoming Phase 2 SOLSTICE data presentation sharpens attention on the hepatitis delta program, which remains the key near term clinical catalyst, while the biggest risk is that pivotal ECLIPSE and later stage trials fail to deliver the regulatory outcomes needed to justify ongoing cash burn and recent dilution.

The Astellas collaboration around VIR 5500 is especially relevant here, because it underpins Vir’s dual focus on infectious disease and oncology while bringing in US$335 million in upfront and near term funding and cost sharing for development. That financial support may help bridge Vir to later hepatitis delta readouts, but it does not remove the core risk that expensive, multi asset trials extend the company’s loss making period if regulatory progress is slower than expected.

Yet many investors may be underestimating how a delay in hepatitis delta approvals could extend losses and pressure Vir’s ability to avoid further dilution...

Vir Biotechnology's narrative projects $141.9 million revenue and $18.3 million earnings by 2029.

Uncover how Vir Biotechnology's forecasts yield a $20.78 fair value, a 126% upside to its current price.

Exploring Other Perspectives

Before this update, the most bearish analysts were assuming Vir’s revenue could fall about 56 percent a year and still doubted profitability, which is a far more pessimistic view than the upside many see in the accelerating hepatitis delta program you are now watching.

Explore 2 other fair value estimates on Vir Biotechnology - why the stock might be worth just $12.00!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Vir Biotechnology research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Vir Biotechnology research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Vir Biotechnology's overall financial health at a glance.

Looking For Alternative Opportunities?

Our top stock finds are flying under the radar-for now. Get in early:

• Explore 28 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 46 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.